BCS Private Wealth Management Inc. Buys New Stake in Danaher Corporation $DHR

BCS Private Wealth Management Inc. purchased a new position in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,144 shares of the conglomerate’s stock, valued at approximately $1,809,000.

A number of other institutional investors also recently added to or reduced their stakes in DHR. iSAM Funds UK Ltd boosted its stake in Danaher by 86.0% in the 2nd quarter. iSAM Funds UK Ltd now owns 2,827 shares of the conglomerate’s stock valued at $558,000 after buying an additional 1,307 shares in the last quarter. AXA S.A. lifted its holdings in shares of Danaher by 26.8% during the second quarter. AXA S.A. now owns 335,777 shares of the conglomerate’s stock valued at $66,329,000 after acquiring an additional 71,060 shares during the period. Lombard Odier Asset Management Switzerland SA boosted its stake in shares of Danaher by 19.2% in the 2nd quarter. Lombard Odier Asset Management Switzerland SA now owns 24,392 shares of the conglomerate’s stock valued at $4,818,000 after purchasing an additional 3,930 shares in the last quarter. Fayez Sarofim & Co grew its holdings in shares of Danaher by 1.0% in the 2nd quarter. Fayez Sarofim & Co now owns 8,538 shares of the conglomerate’s stock worth $1,687,000 after purchasing an additional 84 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of Danaher by 8.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 134,629 shares of the conglomerate’s stock worth $26,595,000 after purchasing an additional 10,126 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is currently owned by insiders.

Danaher Stock Performance

Shares of Danaher stock opened at $223.51 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm has a 50 day simple moving average of $217.50 and a 200 day simple moving average of $205.01. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The firm has a market cap of $157.87 billion, a P/E ratio of 46.08, a P/E/G ratio of 4.36 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Robert W. Baird set a $247.00 price target on shares of Danaher in a research report on Wednesday, October 22nd. Morgan Stanley assumed coverage on shares of Danaher in a research note on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Barclays boosted their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft raised their price target on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Finally, Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $246.79.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.